Citius Oncology, Inc. filed a Form 8-K on November 4, 2026, announcing that it issued a press release presenting health-related quality of life results from pivotal Study 302 of LYMPHIR (denileukin diftitox-cxdl) at the EORTC-CLTG 2026 Annual Meeting.
Key Highlights
- Product featured: LYMPHIR (denileukin diftitox-cxdl), studied in adults with relapsed or refractory cutaneous T-cell lymphoma.
- Data presented: Health-related quality of life results from pivotal Study 302, according to the filing.
- Conference: Results were presented at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) 2026 Annual Meeting.
- Event date: The press release was issued and the report dated November 4, 2026.
- Signatory: The filing was signed by Leonard Mazur, Chairman and Chief Executive Officer.
- Emerging growth company: The registrant indicated it qualifies as an emerging growth company under applicable SEC rules.
Citius Oncology Reports Study 302 Quality-of-Life Findings for LYMPHIR
Citius Oncology, Inc. (NASDAQ:CTOR), headquartered at 11 Commerce Drive, 1st Floor, Cranford, NJ 07016, submitted a current report on November 4, 2026, disclosing that the company issued a press release on the same date. According to the filing, the press release announced health-related quality of life results from pivotal Study 302 of LYMPHIR (denileukin diftitox-cxdl) in adults with relapsed or refractory cutaneous T-cell lymphoma.
The filing states that these results were presented at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) 2026 Annual Meeting. The press release itself, dated November 4, 2026, was filed as Exhibit 99.1 to the current report. No financial results, specific clinical outcome figures, or additional study data were included in the body of the 8-K itself; the substantive content of the data presentation is contained within the attached press release exhibit.
The report was filed under Item 8.01 (Other Events) and signed by Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology, Inc. The company identified itself as an emerging growth company as defined under Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934, and indicated it has not elected to use the extended transition period for complying with new or revised financial accounting standards.
What Was Disclosed
Citius Oncology filed an 8-K on November 4, 2026, to report the issuance of a press release announcing health-related quality of life results from pivotal Study 302 of LYMPHIR in relapsed or refractory cutaneous T-cell lymphoma, presented at the EORTC-CLTG 2026 Annual Meeting.



Please wait processing your request...